Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 5/2015

01-05-2015 | Letter to the Editor

Remission induction with lenalidomide in a patient with relapsed diffuse large B cell lymphoma of the leg type

Authors: Abhisek Swaika, David M. Menke, Manoj K. Jain, Taimur Sher

Published in: Annals of Hematology | Issue 5/2015

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Senff NJ, Hoefnagel JJ, Jansen PM, Vermeer MH, Van Baarlen J, Blokx WA, Canninga-van Dijk MR, Geerts ML, Hebeda KM, Kluin PM, Lam KH, Meijer CJLM, Willemze R (2007) Reclassification of 300 primary cutaneous B-cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers. J Clin Oncol 25:1581–1587CrossRefPubMed
2.
Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, Ralfkiaer E, Chimenti S, Diaz-Perez JL, Duncan LM, Grange F, Harris NL, Kempf W, Kerl H, Kurrer M, Knobler R, Pimpinelli N, Sander C, Santucci M, Sterry W, Vermeer MH, Wechsler J, Whittaker S, Meijer CJLM (2005) WHO-EORTC classification for cutaneous lymphomas. Blood 105:3768–3785CrossRefPubMed
3.
Senff NJ, Willemze R (2007) The applicability and prognostic value of the new TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome: results on a large cohort of primary cutaneous B-cell lymphomas and comparison with the system used by the Dutch Cutaneous Lymphoma Group. Brit J Dermatol 157:1205–1211CrossRef
4.
Grange F, Bekkenk MW, Wechsler J, Meijer CJLM, Cerroni L, Bernengo M, Bosq J, Hedelin G, Fink Puches R, Van Vloten WA, Joly P, Bagot M, Willemze R (2001) Prognostic factors in primary cutaneous large B-cell lymphomas: a European multicenter study. J Clin Oncol 19:3602–3610PubMed
5.
Senff NJ, Hoefnagel JJ, Neelis KJ, Vermeer MH, Noordijk EM, Willemze R (2007) Results of radiotherapy in 153 primary cutaneous B-cell lymphomas classified according to the WHO-EORTC classification. Arch Dermatol 143:1520–1526CrossRefPubMed
6.
Senff NJ, Noordijk EM, Kim YH, Bagot M, Berti E, Cerroni L, Dummer R, Duvic M, Hoppe RT, Pimpinelli N, Rosen ST, Vermeer MH, Whittaker S, Willemze R (2008) European Organization for Research and Treatment of Cancer and International Society for cutaneous lymphoma Consensus recommendations for the management of cutaneous B-cell lymphomas. Blood 112:1600–1609CrossRefPubMed
7.
Witzig TE, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Polikoff JA, Bouabdallah R, Haioun C, Tilly H, Guo P, Pietronigro D, Ervin-Haynes AL, Czuczman MS (2011) An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma. Ann Oncol 22:1622–1627CrossRefPubMed
8.
Nowakowski GS, LaPlant B, Macon WR, Reeder CB, Foran JM, Nelson GD, Thompson CA, Rivera CE, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Ansell SM, Habermann TM, Witzig TE (2014) Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a Phase II Study. J Clin Oncol
9.
Savini P, Lanzi A, Foschi FG, Marano G, Stefanini GF (2014) Lenalidomide monotherapy in relapsed primary cutaneous diffuse large B cell lymphoma-leg type. Ann Hematol 93:333–334CrossRefPubMed
Metadata
Title
Remission induction with lenalidomide in a patient with relapsed diffuse large B cell lymphoma of the leg type
Authors
Abhisek Swaika
David M. Menke
Manoj K. Jain
Taimur Sher
Publication date
01-05-2015
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 5/2015
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-014-2253-3

Other articles of this Issue 5/2015

Annals of Hematology 5/2015 Go to the issue

Original Article

Efficacy of Helicobacter pylori eradication for the 1st line treatment of immune thrombocytopenia patients with moderate thrombocytopenia

Original Article

Comparison and evaluation of three screening tests of hereditary spherocytosis in Chinese patients

Letter to the Editor

Calreticulin mutations are not present in patients with myeloproliferative chronic myelomonocytic leukemia

Letter to the Editor

Mutational analysis of oncogenic CSF3R p.T618I in acute leukemias and common solid cancers

Original Article

Multiparameter FLAER-based flow cytometry for screening of paroxysmal nocturnal hemoglobinuria enhances detection rates in patients with aplastic anemia

Letter to the Editor

Paraneoplastic pyoderma gangrenosum with posttransplant lymphoproliferative disorder
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits